Glatopa

The U.S. Food and Drug Administration's approval of Mylan N.V. (NASDAQ: MYL)'s generic version of Copaxone for the treatment of relapsing multiple sclerosis should be seen as a "clear negative" for Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s Glatopa franchise, analysts at Baird said. The firm's...

Offering its insight into the formulary coverage of multiple sclerosis drugs for 2017, Bernstein said in a note released on Thursday it sees stabilization of formulary coverage after a year of tightening in 2016. Treatment Options MS is a neurodegenerative disease affecting young adults,...